Effervescent tablet formulation of Vitamin C for direct compression
Formulation Guideline

Effervescent tablet formulation of Vitamin C for direct compression

Vitamin C formulation demonstrating the excellent properties of SweetPearl® P300 DC maltitol as directly compressible excipient for effervescent tablets

Objective

Realize a formulation for effervescent tablet made by direct compression. The tablet must present quick effervescent time and offer good stability of the API.


Formula

Ingredient

Functionality of the ingredient

mg/tablet

(total weight: 2400mg)

% by weight

Ascorbic acid

Active Ingredient

250

10.4

SweetPearl® P300 DC maltitol

Direct compression filler-binder

995

41.5

Effervescent mix (citric acid and sodium bicarbonate)  

Effervescent system

900

37.5

Sucralose

High intensity sweetener

8

0.3

Tropical punch flavor

Flavor

28

1.1

Flour salt

Flavor

3

0.1

Masking type flavor

Flavor

28

1.1

Sodium benzoate

Lubricant

100

4.2

Polyethylene glycol 4000, powder

Lubricant

90

3.8

 

Method

  1. In a mixer, mix the ingredients for 5 minutes.
  2. Compress the powder with a 20 mm flat punch.

 


Additional comments

Hardness

100 N

Friability test

Passed

Effervescence time

≤ 2 min (in 200 mL of water)

API stability

improved in comparison to sorbitol-based tablets

Tablet mass

2400 mg

SweetPearl® P300 DC is a granulated free-flowing maltitol specifically designed for direct compression. Distinctive physicochemical properties of maltitol make it an excellent excipient for effervescent formulations as it gives good hardness at low compression force, while reaching a density high enough so that the tablet remains in the bottom of the glass, ensuring a short effervescence time. SweetPearl® P300 DC is low hygroscopic, chemically stable, inert, but at the same time, water soluble. It is a non-cariogenic and non-acidogenic sugar-free sweetener.

SweetPearl® P300 DC is EP/USP-NF compliant.


Disclaimer

This formula is a guideline for recommended use of our products; it does not imply consent to their use in violation of existing patent(s). 
These details are for information only, and we believe them to be reliable.